Coverage
Filings
| Filing | Date |
|---|---|
| Treasury Stock | 3 Jul 2007 |
| Total voting rights | 29 Jun 2007 |
| Research Update | 21 Jun 2007 |
| These Articles of Association were adopted on 19 June 2007. | 19 Jun 2007 |
| Transaction in Own Shares | 19 Jun 2007 |
| Miscellaneous | 1 Jun 2007 |
| Disposal | 31 May 2007 |
| Director/PDMR Shareholding | 10 May 2007 |
| Director/PDMR Shareholding |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 8 May 2007 |
| Director/PDMR Shareholding | 7 May 2007 |
| Director/PDMR Shareholding | 3 May 2007 |
| 1st Quarter Results | 2 May 2007 |